International Federation of Gynecology and Obstetrics

Combining human papillomavirus (HPV) testing with routine liquid-based cytology (LBC) screening does not increase cervical cancer detection rates, a new UK study has indicated.

Research published in the edition of The Lancet Oncology suggests that there may be no benefits to conducting both tests when seeking precancerous cervical cells.

The article explains that the liquid form of the Pap smear test – LBC - has replaced conventional Pap smears in the UK after delivering improved results – with 70 per cent of cancers now avoided.

However, it had been queried whether prevention rates could be improved further by conducting dual tests with the two techniques.

After concluding their study, authors of the Artistic report stated: "Over two rounds this trial showed no evidence that LBC combined with HPV testing in primary cervical screening detected more CIN2 or CIN3+ than cytology alone.

"This summed effect over two rounds is relevant because screening relies on repeated rounds to achieve its sensitivity."

Earlier this month, the World Health Organization granted pre-qualification status to a four-type HPV vaccine – Gardasil.